# LALPATHLAB (LALPATHLAB) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/lalpathlab

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,892.1
- Change: -1.69%
- As of: 2026-09-18
- 1D return: -1.44%
- 5D return: -1.03%
- 1M return: +0.40%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, LALPATHLAB is exhibiting a mixed technical stance across different timeframes. The daily trend shows bullish signals with the price above the Supertrend indicator (1793.04) and the 50-day Simple Moving Average (1864.3), though it is below the 20-day Exponential Moving Average (1905.57). The weekly and monthly timeframes also indicate bullish trends, with prices trading above their respective Supertrend, 20-day EMA, and 50-day EMA indicators. However, the monthly chart shows active reversal patterns including a "Bearish Engulfing Reversal" and an "Outside Bar" as of September 18, 2026, suggesting potential short-term caution despite the longer-term bullish indicators. The stock's current price of ₹1896.9 is positioned within its 20-day range, approximately 23% from the low end. Volatility is noted with an annualized volatility of 29% and an Average True Range (ATR) of 3.03% of the price.

- Nearest support is observed at ₹1894.77, approximately 0.11% below the current price.
- Nearest resistance is identified at ₹1917.93, approximately 1.11% above the current price.
- Monthly chart shows active "Bearish Engulfing Reversal" and "Outside Bar" patterns as of September 18, 2026.
- Daily timeframe shows the price below the 20-day EMA (1905.57) but above the 50-day SMA (1864.3).
- Watch for a sustained move above ₹1917.93 for potential strengthening of the bullish trend, and a break below ₹1894.77 to test lower support levels.

- Bearish Engulfing Reversal
- Outside Bar
- Doji
- Harami
- Bullish Engulfing Reversal
- Inside Bar
- Evening Star

### News Context

The diagnostics sector is expected to see sustained volume growth through fiscal year 2027, according to brokerage expectations. This outlook is supported by stable pricing and increasing demand from the business-to-consumer (B2C) segment, potentially benefiting from operating leverage. Separately, MarketSmith India provided stock recommendations on September 16, 2026, offering expert insights for investors.

- Brokerages anticipate continued volume growth for listed diagnostics companies through FY27, citing stable pricing and B2C demand.
- Operating leverage is expected to contribute to the diagnostics sector's performance.
- MarketSmith India issued stock recommendations on September 16, 2026.

- Stock recommendations for 16 September from MarketSmith India
- Robust demand, pricing to keep volumes strong for diagnostics sector

### What Changed

As of September 18, 2026, Dr. Lal Path Labs (LALPATHLAB) on the NSE has experienced a slight price decrease, closing at ₹1896.9 compared to its previous price of ₹1924.7. The available data does not indicate any new filings or news developments for the company during this recent period. The company's profile and listing on the NSE remain unchanged from prior context.

- On September 18, 2026, the closing price for LALPATHLAB was ₹1896.9.
- The previous closing price for LALPATHLAB was ₹1924.7.
- No new filings or news developments were reported for LALPATHLAB as of September 18, 2026.
- Dr. Lal Path Labs continues to be listed on the NSE.

### Official Filings

Dr. Lal PathLabs Limited has recently disclosed several strategic and operational updates. On August 27, 2026, the company, through its wholly-owned subsidiary Dr. Lal Ventures Private Limited, completed the acquisition of a 30% stake in Neuome Technologies Private Limited for ₹35,000,000. This move makes Neuome an associate company, potentially expanding the group's service offerings or market reach. Further international expansion was signaled on August 19, 2026, with the incorporation of Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan. This step-down subsidiary, in which Dr. Lal PathLabs FZCO (a wholly-owned subsidiary) will hold a 70% stake, aims to strengthen the group's presence in the Uzbek diagnostic services market. The company also published newspaper advertisements on September 4, 2026, regarding unclaimed interim dividends from FY 2019-20, which are due for transfer to the Investor Education and Protection Fund (IEPF). Separately, disclosures regarding insider trading show various transactions by promoters and designated persons, primarily related to Employee Stock Option Plans (ESOPs). These include acquisitions and subsequent sales of shares by individuals like Amit Aggarwal and Jai Prakash Meena, as well as transactions by the Dr. Lal PathLabs Employee Welfare Trust.

- On August 27, 2026, Dr. Lal Ventures Private Limited acquired a 30% stake in Neuome Technologies Private Limited for ₹35,000,000, making Neuome an associate company.
- On August 19, 2026, a step-down subsidiary, Dr Lal PathLabs Indomed LLC, was incorporated in Uzbekistan to enhance the group's presence in that market.
- On September 4, 2026, the company published notices regarding unclaimed interim dividends from FY 2019-20 due for transfer to the IEPF.
- Disclosures filed on September 3, 2026, and August 24, 2026, detail promoter and employee trust share transactions, including ESOP exercises and market sales.
- Disclosures filed on August 25, 2026, and August 20, 2026, show share acquisitions and sales by designated persons under ESOP plans.

- Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- LALPATHLAB|DR. LAL PATHLABS LIMITED|Original|Regulation 7 (2)|IT_13310_WebXMLFile_20260903_175134479.xml|IT_13310_20260903_175134520_WEB.html|14954|44995|-
- Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates |SUBJECT: General Updates
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL |SUBJECT: Update-Acquisition (including agreement to acquire)-XBRL
- LALPATHLAB|DR. LAL PATHLABS LIMITED|Original|Regulation 7 (2)|IT_13310_WebXMLFile_20260825_165645047.xml|IT_13310_20260825_165645081_WEB.html|8345|29962|-
- LALPATHLAB|DR. LAL PATHLABS LIMITED|Original|Regulation 7 (2)|IT_13310_WebXMLFile_20260824_180746424.xml|IT_13310_20260824_180746461_WEB.html|8469|30188|-
- LALPATHLAB|DR. LAL PATHLABS LIMITED|Revision|Regulation 7 (2)|IT_13310_WebXMLFile_20260820_183444119.xml|IT_13310_20260820_183444152_WEB.html|5694|24114|Revised Submission
- Incorporation of a Step-Down Subsidiary Company |SUBJECT: General Updates
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL

### Fundamentals

Dr. Lal Path Labs has demonstrated a consistent upward trend in its revenue from operations over the reported periods. Revenue grew from ₹659.80 crore in Q3 FY2025-26 to ₹797.70 crore in Q1 FY2026-27. This revenue growth has been accompanied by an increase in Profit Loss For Period, which rose from ₹91.40 crore in Q3 FY2025-26 to ₹170.50 crore in Q1 FY2026-27. The company's expenses have also increased, from ₹529.80 crore in Q3 FY2025-26 to ₹600.90 crore in Q1 FY2026-27, but the profit before tax has grown at a faster pace, indicating potential operating leverage. Finance costs have remained relatively stable, fluctuating between ₹6.10 crore and ₹7.20 crore across the observed quarters. The tax expense has varied, with a notable increase in Q1 FY2026-27 to ₹58.20 crore compared to ₹32.90 crore in Q3 FY2025-26.

- Revenue from operations increased sequentially from ₹659.80 crore in Q3 FY2025-26 to ₹797.70 crore in Q1 FY2026-27.
- Profit Loss For Period grew from ₹91.40 crore in Q3 FY2025-26 to ₹170.50 crore in Q1 FY2026-27.
- Expenses rose from ₹529.80 crore in Q3 FY2025-26 to ₹600.90 crore in Q1 FY2026-27.
- Finance Costs remained between ₹6.10 crore and ₹7.20 crore from Q3 FY2025-26 to Q1 FY2026-27.
- Tax Expense was ₹32.90 crore in Q3 FY2025-26 and ₹58.20 crore in Q1 FY2026-27.

### Bull Case

The company's stock exhibits a constructive technical setup across multiple timeframes as of September 18, 2026. Daily, weekly, and monthly trends are all indicated as bullish, supported by positive Supertrend indicators and moving average slopes. This technical strength is occurring within a sector that is expected to maintain volume growth through FY27, driven by stable pricing and consumer demand, according to brokerage expectations.

- The daily trend analysis shows a bullish Supertrend direction with the close price (₹1896.9) above the 20-day Exponential Moving Average (EMA) (₹1905.57) and 50-day Simple Moving Average (SMA) (₹1864.3).
- The weekly trend analysis also indicates a bullish Supertrend direction, with the close price (₹1896.9) above both the 20-day EMA (₹1760.44) and 50-day EMA (₹1625.8).
- The monthly trend analysis confirms a bullish Supertrend direction, with the close price (₹1896.9) trading above the 20-day EMA (₹1582.62) and 50-day SMA (₹1520.74).
- Brokerages anticipate the diagnostics sector, including listed majors, to maintain volume growth through FY27, citing stable pricing and robust B2C demand.

- Stock recommendations for 16 September from MarketSmith India
- Robust demand, pricing to keep volumes strong for diagnostics sector

### Bear Case

The company's stock price is currently trading near a resistance level, with the nearest pivot resistance identified at ₹1917.93. While the daily and weekly trends indicate a bullish Supertrend direction, the price is also close to its 20-day Exponential Moving Average (EMA) of ₹1905.57. The stock has experienced a drawdown of 4% from its recent peak and a maximum drawdown of 25% historically. Annualized volatility stands at 29%.

- The stock's closing price on 2026-09-18 was ₹1896.9.
- Nearest resistance level identified at ₹1917.93.
- Current drawdown is 4%, with a maximum historical drawdown of 25%.
- Annualized volatility is 29%.

- Stock recommendations for 16 September from MarketSmith India
- Robust demand, pricing to keep volumes strong for diagnostics sector

### FAQs

**What recent strategic investments has Dr. Lal Path Labs made?**

On August 27, 2026, Dr. Lal Path Labs, through its wholly owned subsidiary Dr. Lal Ventures Private Limited, completed the subscription of a 30% stake in Neuome Technologies Private Limited for ₹35,000,000. This transaction made Neuome Technologies an associate company.

**What were the recent insider trading activities for Dr. Lal Path Labs?**

On September 3, 2026, promoter Amit Aggarwal acquired 1,500 shares via ESOP exercise at ₹1,425.715 per share and subsequently sold the same number of shares on the NSE market. Separately, promoter Jai Prakash Meena purchased 2,000 shares through an ESOP exercise at an effective price of ₹1,087.47 per share, while the Dr. Lal PathLabs Employee Welfare Trust sold 5,700 shares acquired under various ESOP exercises.

**How has Dr. Lal Path Labs performed over different timeframes based on recent data?**

As of September 18, 2026, Dr. Lal Path Labs has shown the following returns: a 15% return over the last year, a 41% return over the last six months, and a 26% return year-to-date. The return since the start of trading is 24%.

**What is the current technical outlook for Dr. Lal Path Labs?**

As of September 18, 2026, the daily trend for Dr. Lal Path Labs is indicated as bullish by the Supertrend indicator at 1793.04. Key technical indicators show a closing price of ₹1896.9, with the 50-day Simple Moving Average (SMA) at ₹1864.3 and the 200-day SMA at ₹1573.91. The stock is trading near its nearest support level of ₹1894.77.

- Stock recommendations for 16 September from MarketSmith India
- Robust demand, pricing to keep volumes strong for diagnostics sector
- Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- LALPATHLAB|DR. LAL PATHLABS LIMITED|Original|Regulation 7 (2)|IT_13310_WebXMLFile_20260903_175134479.xml|IT_13310_20260903_175134520_WEB.html|14954|44995|-
- Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates |SUBJECT: General Updates
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL |SUBJECT: Update-Acquisition (including agreement to acquire)-XBRL
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,917.93
- Risk regime: Price Risk Currently Contained

### Support levels
- 1862.9
- 1611.7875
- 1551

### Resistance levels
- 1960.525
- 1988.9
- 1947.8666666666668

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -1.44% |
| return_10 | -1.47% |
| return_1m | -0.24% |
| return_1y | +15.47% |
| return_20 | +0.40% |
| return_3m | +14.07% |
| return_5 | -1.03% |
| return_6m | +40.83% |
| return_since_start | +24.26% |
| return_ytd | +25.64% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -25.48% |
| annualized_volatility | +29.02% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Profit Expand Faster Than Costs; Per-Share Earnings Decline

Dr. Lal PathLabs reported higher revenue and net profit for the first quarter of fiscal 2026-27 compared to the same period last year. Operating expenses grew more slowly than sales, supporting a rise in pre-tax earnings. However, basic earnings per share fell significantly because the number of shares outstanding increased substantially over the past year.

## Revenue Growth

Revenue from operations reached ₹797.70 crore for the quarter ended 30 June 2026, up 19.1% from ₹669.80 crore a year earlier. Sequentially, revenue rose 13.5% from ₹702.70 crore in the preceding quarter. This marks the highest quarterly revenue observed, exceeding the previous peak of ₹730.60 crore in the second quarter of the prior fiscal year.

## Expense Management and Profitability

Total expenses increased 16.3% year-on-year to ₹600.90 crore, growing at a slower pace than revenue. As a percentage of revenue from operations, total expenses declined to 75.3% from 77.2% in the prior-year quarter. This shift contributed to a 26.3% year-on-year increase in profit before tax to ₹228.70 crore. Finance costs were ₹6.30 crore, up from ₹4.70 crore a year ago but remaining a small portion of overall expenses. The effective tax rate was 25.5%, down slightly from 26.0% in the same quarter last year. Net profit for the period rose 27.2% to ₹170.50 crore.

## Earnings Per Share

Basic earnings per share for the quarter was ₹10.15, down 36.1% from ₹15.88 in the first quarter of the previous fiscal year. This decline occurred even though net profit increased, indicating that the number of shares outstanding has grown substantially. The reported EPS figures for the intervening quarters also reflect variations consistent with a changed share base.

## Key Takeaway

The quarter delivered higher revenue and net profit, with expenses growing more slowly than sales. The primary offset to headline profit growth is a lower basic earnings per share, driven by a larger number of shares outstanding rather than weaker operating results. Investors evaluating the company's earnings should account for the impact of the expanded share count alongside the underlying profit expansion.

### Ratios

## Official filings

- 2026-09-04 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_04092026125623_newspaper_publication_IEPF.pdf)
- 2026-09-03 — Official Filing: DR. LAL PATHLABS LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_13310_WebXMLFile_20260903_175134479.xml)
- 2026-08-27 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_27082026191308_Update_on_Acquisition_Neuome.pdf)
- 2026-08-27 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_13310_WebXMLFile_20260827_192026564.xml)
- 2026-08-27 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_13310_WebXMLFile_20260827_203947389.xml)
- 2026-08-25 — Official Filing: DR. LAL PATHLABS LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_13310_WebXMLFile_20260825_165645047.xml)
- 2026-08-24 — Official Filing: DR. LAL PATHLABS LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_13310_WebXMLFile_20260824_180746424.xml)
- 2026-08-20 — Official Filing: DR. LAL PATHLABS LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_13310_WebXMLFile_20260820_183444119.xml)
- 2026-08-19 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_19082026182503_incorporationofstepdownsubusidiary_uzbek.pdf)
- 2026-08-19 — Generic Announcement: Dr. Lal Path Labs Ltd. — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_13310_WebXMLFile_20260819_183406817.xml)
- 2026-08-18 — Official Filing: DR. LAL PATHLABS LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_13310_WebXMLFile_20260818_180900651.xml)
- 2026-08-06 — Generic Announcement: Dr. Lal PathLabs Limited allotted 2,11,050 equity shares under its ESOP Plan 2022 on August 6, 2026. This allotment increased the company's paid-up equity share capital to INR 1,67,84,88,200, comprising 16,78,48,820 equity shares of INR 10 each. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_06082026161843_ESOPALLOTMENT060826.pdf)
- 2026-07-30 — Generic Announcement: Dr. Lal PathLabs reported Q1 FY27 revenue of Rs. 798 crore, a 19.1% year-on-year increase, marking the highest quarterly growth in four years. This growth was driven by an 8.2% rise in patient volumes and a 10.7% increase in sample volumes. The company also announced the acquisition of an 80% stake in Sunshine Healthcare Limited in Ghana for up to GHS 45.6 million and a 30% stake in Neuome Technologies Private Limited for up to Rs 3.5 crore. An interim dividend of 50% (Rs 5 per share) was declared. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_30072026193041_FINALTranscript30072026.pdf)
- 2026-07-26 — Official Filing: Mr. Gurinder Singh Kalra has completed his tenure as a Non-Executive Independent Director of DR. LAL PATH LABS LTD. on July 26, 2026, and consequently ceases to hold this position effective the same date.
- 2026-07-26 — Generic Announcement: Mr. Gurinder Singh Kalra completed his tenure as an Independent Director of Dr. Lal PathLabs Limited on July 26, 2026, and consequently ceased to hold the position. This information is disclosed in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_26072026200001_GSKstxIntimation.pdf)
- 2026-07-25 — Generic Announcement: Dr. Lal PathLabs Limited published its financial results for the quarter ended June 30, 2026, in the Financial Express and Jansatta newspapers on July 25, 2026, in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_25072026151435_Newspaper.pdf)
- 2026-07-25 — Official Filing: At the 32nd Annual General Meeting on July 25, 2026, DR. LAL PATH LABS LTD. shareholders approved the re-appointment of (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Whole-Time Director for five years starting April 1, 2027. Shareholders also approved the re-appointment of Mr. Rajit Mehta as a Non-Executive Independent Director for a second five-year term commencing July 27, 2026.
- 2026-07-25 — Generic Announcement: Dr. Lal PathLabs Limited held its 32nd Annual General Meeting on July 25, 2026, via video conference. Key agenda items included the adoption of financial statements for the year ended March 31, 2026, declaration of a final dividend of INR 4 per share, and various special business items such as revisions in remuneration structures for executive directors and re-appointments of directors. The results of the e-voting are expected by July 28, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_25072026152553_AGM_Procedding.pdf)
- 2026-07-25 — Generic Announcement: Dr. Lal PathLabs Limited held its 32nd Annual General Meeting on July 25, 2026, via video conference. The meeting included voting on ten resolutions, all of which were passed with requisite majority. Key resolutions included the adoption of audited financial statements for the year ended March 31, 2026, the declaration of a final dividend of INR 4 per share, the re-appointment of directors, and revisions to remuneration structures for certain executive directors. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_25072026165530_Scrutinizer_Report_Final.pdf)
- 2026-07-24 — Generic Announcement: Dr. Lal PathLabs Limited has made available the audio recording of its Q1 FY27 earnings conference call with investors and analysts, held on July 24, 2026. The recording can be accessed on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_24072026191638_audio.pdf)
- 2026-07-24 — Generic Announcement: On July 24, 2026, Dr. Lal PathLabs Limited's Board of Directors approved the un-audited financial results for the quarter ended June 30, 2026, and declared an interim dividend of INR 5 per equity share for FY 2026-27, with a record date of July 30, 2026. The board also approved granting stock options and noted subsidiary approvals for acquisitions: Dr Lal PathLabs FZCO approved acquiring a stake in Sunshine Healthcare Limited (Ghana) for up to GHS 45.6 million, and Dr. Lal Ventures Private Limited approved acquiring a stake in Neuome Technologies Private Limited for up to INR 35 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_24072026134226_BMOUTCOME_24072026.pdf)
- 2026-07-24 — Generic Announcement: On July 24, 2026, Dr. Lal PathLabs Limited's Board of Directors approved the un-audited financial results for the quarter ended June 30, 2026, and declared an interim dividend of INR 5 per equity share for FY 2026-27, with a record date of July 30, 2026. The board also approved granting stock options and noted subsidiary approvals for acquisitions: Dr Lal PathLabs FZCO approved acquiring a stake in Sunshine Healthcare Limited (Ghana) for up to GHS 45.6 million, and Dr. Lal Ventures Private Limited approved acquiring a stake in Neuome Technologies Private Limited for up to INR 35 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_24072026133704_BMOUTCOME_24072026.pdf)
- 2026-07-24 — Official Filing: Dr. Lal Ventures Private Limited, a wholly-owned subsidiary of Dr. Lal Path Labs Ltd., approved the acquisition of a 30% stake in Neuome Technologies Private Limited for up to INR 35 million. The acquisition, aimed at accessing Neuome's innovative sample preservation and biobanking solutions, is expected to be completed by August 31, 2026. Neuome Technologies, incorporated in 2020, operates in the chemical products and innovative solutions sector for diagnostics and healthcare.
- 2026-07-24 — Generic Announcement: On July 24, 2026, Dr. Lal PathLabs Limited's Board of Directors approved the un-audited financial results for the quarter ended June 30, 2026, and declared an interim dividend of INR 5 per equity share for FY 2026-27, with a record date of July 30, 2026. The board also approved granting stock options and noted subsidiary approvals for acquisitions: Dr Lal PathLabs FZCO approved acquiring a stake in Sunshine Healthcare Limited (Ghana) for up to GHS 45.6 million, and Dr. Lal Ventures Private Limited approved acquiring a stake in Neuome Technologies Private Limited for up to INR 35 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_24072026134427_BMOUTCOME_24072026.pdf)
- 2026-07-24 — Generic Announcement: On July 24, 2026, Dr. Lal PathLabs Limited's Board of Directors approved the un-audited financial results for the quarter ended June 30, 2026, and declared an interim dividend of INR 5 per equity share for FY 2026-27, with a record date of July 30, 2026. The board also approved granting stock options and noted subsidiary approvals for acquisitions: Dr Lal PathLabs FZCO approved acquiring a stake in Sunshine Healthcare Limited (Ghana) for up to GHS 45.6 million, and Dr. Lal Ventures Private Limited approved acquiring a stake in Neuome Technologies Private Limited for up to INR 35 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/LALPATHLAB_24072026133913_BMOUTCOME_24072026.pdf)

## News and market events

- 2026-09-16 — Mint: **Stock recommendations for 16 September from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 16 September. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-for-16-september-from-marketsmith-india-11789472199358.html)
- 2026-09-13 — BUSINESS: **Robust demand, pricing to keep volumes strong for diagnostics sector** — Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage — [Source](https://www.business-standard.com/markets/news/markets-news-robust-demand-pricing-to-keep-volumes-strong-for-diagnostics-126091300223_1.html)
- 2026-07-28 — Mint: **Raja Venkatraman recommends three stocks for 28 July | Stock Market News** — Market expert Raja Venkatraman shares his top stock picks for 28 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-28-july-11785153779486.html)
- 2026-07-27 — Economic Times: **Dr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?** — Dr Lal PathLabs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/dr-lal-path-labs-shares-soar-8-after-q1-earnings-beat-estimates-what-nomura-nuvama-other-brokerages-are-saying/articleshow/132652906.cms)
- 2026-07-15 — Mint: **Market strategy: Kotak Equities adds TCS, SBI Life Insurance in model portfolio, raises weight on L&T** — Market strategy: Both TCS and SBI Life have been assigned a weight of 150 basis points (bps) in the brokerage’s model portfolio. The brokerage, however, clarified that TCS's inclusion in the model portfolio should not be interpreted as a broader endorsement of the IT services sector. — [Source](https://www.livemint.com/market/stock-market-news/market-strategy-kotak-equities-adds-tcs-sbi-life-insurance-in-model-portfolio-raises-weight-on-l-and-t-11784106568903.html)

## Business profile

**Strategic vision:** Provider of diagnostic and related healthcare services.

### Business segments
- **Diagnostic and Healthcare Services:** Offers pathology services, operates a blood bank, and provides diagnostic testing through a network of clinical laboratories, patient service centers, and pick-up points.

### Competitive strengths
- Widespread domestic network of clinical laboratories, patient service centers, and pick-up points.
- International operations in multiple countries.
- Logistics strength supported by a network of satellite labs, staff, and doctors.
- NABL-accredited laboratories.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/lalpathlab
Markdown representation: https://faxioms.com/stocks/lalpathlab?render=md